Literature DB >> 16893374

Aminoguanidine prevents arterial stiffening in a new rat model of type 2 diabetes.

K-C Chang1, C-D Tseng, M-S Wu, J-T Liang, M-S Tsai, Y-L Cho, Y-Z Tseng.   

Abstract

BACKGROUND: Formation of advanced glycation end-products (AGEs) on collagen within the arterial wall may be responsible for the development of diabetic vascular injury. This study focused on investigating the role of aminoguanidine (AG), an inhibitor of AGE formation, in the prevention of noninsulin-dependent diabetes mellitus (NIDDM)-derived arterial stiffening and cardiac hypertrophy in rats.
MATERIALS AND METHODS: The NIDDM was induced in male Wistar rats, which were administered intraperitoneally with 180 mg kg(-1) nicotinamide (NA) 30 min before an intravenous injection of 50 mg kg(-1) streptozotocin (STZ). After induction of diabetes mellitus type 2, animals receiving daily peritoneal injections with 50 mg kg(-1) AG for 8 weeks were compared with the age-matched, untreated, diabetic controls.
RESULTS: After exposure to AG, the STZ-NA diabetic rats had improved aortic distensibility, as evidenced by 18.8% reduction of aortic characteristic impedance (P < 0.05). Treatment of the experimental syndrome with AG also resulted in a significant increase in wave transit time (+23.7%, P < 0.05) and a decrease in wave reflection factor (-26.6%, P < 0.05), suggesting that AG may prevent the NIDDM-induced augmentation in systolic load of the left ventricle. Also, the glycation-derived modification on aortic collagen was found to be retarded by AG. The diminished ratio of left ventricular weight to body weight suggested that prevention of the diabetes-related cardiac hypertrophy by AG may correspond to the drug-induced decline in aortic stiffening.
CONCLUSIONS: Long-term administration of AG to the STZ-NA diabetic rats imparts significant protection against the NIDDM-derived impairment in vascular dynamics, at least partly through inhibition of the AGE accumulation on collagen in the arterial wall.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16893374     DOI: 10.1111/j.1365-2362.2006.01672.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  11 in total

1.  Aminoguanidine prevents fructose-induced deterioration in left ventricular-arterial coupling in Wistar rats.

Authors:  K-C Chang; J-T Liang; C-D Tseng; E-T Wu; K-L Hsu; M-S Wu; Y-T Lin; Y-Z Tseng
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

2.  Effects of aminoguanidine and vitamin C on collagen type IV in diabetic nephropathy rats.

Authors:  Qiangxiang Li; Xiang Ao; Youhong Du; Yang Li; Yangshi Ou; Raofeng Gong; Xuexiong Sun; Yi Xiang Yang; Gebo Wen
Journal:  Endocrine       Date:  2010-11-18       Impact factor: 3.633

3.  Diabetic cardiomyopathy: how much does it depend on AGE?

Authors:  M Montagnani
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

4.  Soluble receptor for advanced glycation end products and increased aortic stiffness in the general population.

Authors:  Otto Mayer; Jitka Seidlerová; Jan Filipovský; Petra Vágovičová; Peter Wohlfahrt; Renata Cífková; Jindra Windrichová; Ondřej Topolčan
Journal:  Hypertens Res       Date:  2015-12-03       Impact factor: 3.872

5.  Aminoguanidine prevents the impairment of cardiac pumping mechanics in rats with streptozotocin and nicotinamide-induced type 2 diabetes.

Authors:  M-S Wu; J-T Liang; Y-D Lin; E-T Wu; Y-Z Tseng; K-C Chang
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

6.  Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes.

Authors:  Sho-Ichi Yamagishi; Nobutaka Nakamura; Mika Suematsu; Kuniyoshi Kaseda; Takanori Matsui
Journal:  Mol Med       Date:  2015-10-27       Impact factor: 6.354

7.  Effects of olmesartan on arterial stiffness in rats with chronic renal failure.

Authors:  Yao-Chen Chuang; Ming-Shiou Wu; Yi-Kai Su; Kwang-Ming Fang
Journal:  Cardiovasc Diabetol       Date:  2012-06-13       Impact factor: 9.951

Review 8.  Advanced glycation end products (AGEs) and its receptor, RAGE, modulate age-dependent COVID-19 morbidity and mortality. A review and hypothesis.

Authors:  Durai Sellegounder; Parisa Zafari; Misagh Rajabinejad; Mahdi Taghadosi; Pankaj Kapahi
Journal:  Int Immunopharmacol       Date:  2021-05-24       Impact factor: 5.714

9.  Advanced Glycation End Products Impair Voltage-Gated K+ Channels-Mediated Coronary Vasodilation in Diabetic Rats.

Authors:  Wen Su; Weiping Li; Hui Chen; Huirong Liu; Haixia Huang; Hongwei Li
Journal:  PLoS One       Date:  2015-11-12       Impact factor: 3.240

Review 10.  Arterial stiffness and cardiovascular therapy.

Authors:  Miodrag Janić; Mojca Lunder; Mišo Sabovič
Journal:  Biomed Res Int       Date:  2014-08-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.